PP2A-Aα Antibody (6F9): sc-56953
- PP2A-Aα Antibody (6F9) is a rat monoclonal IgG2a, cited in 1 publications, provided at 200 µg/ml
- raised against the N-terminus of PP2A-Aα of human origin
- recommended for detection of PP2A-Aα of mouse, rat, human and porcine origin by WB, IP, IF and IHC(P)
- See PP2A-Aα (6G3): sc-56954 for PP2A-Aα antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for PP2A-Aα Antibody (6F9). This work is in progress.
QUICK LINKS
SEE ALSO...
PP2A-Aα Antibody (6F9) is a rat monoclonal IgG2a antibody that detects PP2A-Aα in mouse, rat, human, and porcine samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. PP2A-Aα is a crucial regulatory subunit of the protein phosphatase 2A (PP2A) complex, which plays a vital role in cellular signaling pathways by dephosphorylating serine and threonine residues on target proteins. This dephosphorylation is essential for regulating numerous cellular functions such as cell division, apoptosis, and maintaining cellular homeostasis. The PP2A complex is composed of a catalytic subunit and a regulatory subunit, with PP2A-Aα serving as one of the key regulatory components that modulate catalytic subunit activity. PP2A-Aα interaction with associated catalytic subunit ensures proper functioning of the PP2A holoenzyme, influencing various signaling pathways implicated in cancer and other diseases. Understanding PP2A-Aα dynamics and interactions can provide insights into therapeutic targets for diseases characterized by dysregulated phosphorylation states.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
PP2A-Aα Antibody (6F9) References:
- Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. | McConechy, MK., et al. 2011. J Pathol. 223: 567-73. PMID: 21381030
- Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. | Shih, IeM., et al. 2011. Am J Pathol. 178: 1442-7. PMID: 21435433
- PPP2R1A mutations are common in the serous type of endometrial cancer. | Nagendra, DC., et al. 2012. Mol Carcinog. 51: 826-31. PMID: 21882256
- Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer. | Wang, F., et al. 2013. Mol Med Rep. 7: 1826-30. PMID: 23588898
- Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. | Haesen, D., et al. 2016. Cancer Res. 76: 5719-5731. PMID: 27485451
- Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. | Miron, J., et al. 2019. Neurobiol Aging. 81: 234-243. PMID: 31349112
- A Cancer-Associated Missense Mutation in PP2A-Aα Increases Centrosome Clustering during Mitosis. | Antao, NV., et al. 2019. iScience. 19: 74-82. PMID: 31357169
- Advanced Optical Microscopy: Unveiling Functional Insights Regarding a Novel PPP2R1A Variant and Its Unreported Phenotype. | Roldán, M., et al. 2023. Int J Mol Sci. 24: PMID: 37762002
- The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism. | Remmerie, M., et al. 2024. Cell Oncol (Dordr). 47: 1811-1829. PMID: 38888850
- BRG1 promotes progression of B-cell acute lymphoblastic leukemia by disrupting PPP2R1A transcription. | Kang, Q., et al. 2024. Cell Death Dis. 15: 621. PMID: 39187513
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PP2A-Aα Antibody (6F9) | sc-56953 | 200 µg/ml | $322.00 |